

CURRICULUM VITAE
OF
ROBERT M. SNAPKA, PH.D.

Professor
Department of Radiology
103 Wiseman Hall
400 W. 12th Avenue
Columbus, Ohio 43210

June 2000

CURRICULUM VITAE

Robert M. Snapka

Address: Department of Radiology, Division of Radiobiology
The Ohio State University
Room 103 Wiseman Hall, 400 W. 12th Avenue
Columbus, Ohio 43210

Telephone: (614) 292-9375 Fax: (614) 292-7237
E-Mail: snapka.1@osu.edu

EDUCATION

- 1978 Ph.D. Molecular Biology and Biochemistry, University of California, Irvine, CA
Advisor: Dr. B.M. Sutherland
1973 M.S. Chemistry, North Texas State University, Denton TX
Advisor: Dr. R.W. Gracy
1970 B.S. Biology, North Texas State University, Denton, TX

EXPERIENCE

TEACHING

- July 1997-Present **Professor**, The Ohio State University, Departments of Radiology, Medical Microbiology and Immunology, and Medical Biochemistry.
July 1990-June 1997 **Associate Professor**, The Ohio State University, Departments of Radiology, Medical Microbiology and Immunology, and Medical Biochemistry.
Aug 1989 - Present **Member**, The Ohio State University, Biochemistry Program
Feb 1989 - Present **Member**, The Ohio State University, Molecular, Cellular and Developmental Biology Program.
Mar 1985 - June 1990 **Assistant Professor**, The Ohio State University, Department of Radiology.
Aug 1987 - June 1990 **Assistant Professor**, The Ohio State University, Department of Medical Microbiology and Immunology, and Department of Physiological Chemistry

RESEARCH

- Jul 1988 - Present Member, The Ohio State University, Comprehensive Cancer Center
Jan 1982 - Feb 1985 Research Associate, MIT, Department of Biology
May 1978 - Jan 1982 Postdoctoral Research Fellow, Department of Biochemistry, U.C. Berkeley
Sep 1977- May 1978 Predoctoral Research, Brookhaven National Laboratory
Sep 1974 - Sep 1977 Predoctoral Research, Department Molecular Biology, U.C. Irvine

1. *Undergraduate, Graduate and Professional Courses Taught*

Radiology 850

Seminars in Radiobiology/1 credit hour

Course Director: Robert M. Snapka

Course Description: Seminar series with emphasis on cellular responses to stressors such as radiation, genotoxic compounds and cytotoxic drugs.

Medical Microbiology 999/Radiology 999/MCD Biol. 999

Research/3-14 credit hours

Course Director: Robert M. Snapka

Course Description: Doctoral thesis research

Medical Microbiology 841

Viral Oncology/3 credit hours

Course Director: James Shaw

Course Description: Viral Oncology. The course covers the principles of viral oncology, including DNA and RNA tumor viruses, viral oncogenes and molecular mechanisms of viral carcinogenesis.

Radiation Biology 680

Radiation Biology/2 credit hours

Course Director: Robert M. Snapka

Course Description: Effects of ionizing radiation on living organisms. Details of radiation damage at the molecular, cellular, organ and whole organism levels are covered. Special emphasis is placed on radiation safety and risk due to medical, occupational and environmental exposure.

Physiological Chemistry (Now Medical Biochemistry) 827

Biochemical Mechanisms of Carcinogenesis/3 credit hours

Course Organizer: George Milo (Winter Quarter, 1988, 1990, 1992, 1994)

Course Description: In depth studies of mechanisms of carcinogenesis.

Course Organizer: F. Robertson (Winter Quarter, 1996)

Pathology-Veterinary Pathology 640

Fundamentals of Oncology/4 credit hours

Course Directors: Charles Capen and Rolf Barth

Course Description: Lectures on experimental oncology. The course covers carcinogenesis, tumor progression, metastasis, epidemiology, biochemistry and molecular biology of cancer as well as the principles of cancer therapy.

Medical Microbiology 754

Medical Virology/4 credit hours

Course Organizer: John Hughes (Spring Quarter, 1990)

Course Description: Survey of medical virology.

Fundamentals of Molecular Virology/5 credit hours

Course Organizer: Deborah Parris (Spring Quarter, 1996)

Course Description: In depth survey of Molecular Virology. The course was greatly expanded and updated, and the emphasis was shifted to molecular biology. The course was changed to 5 credit hours to reflect the increase in content.

Med II 625

Pathophysiology and Manifestation of Disease/4 credit hours

Course Director: Robert O'Toole

Course Description: Multidisciplinary presentation of disease mechanisms.

Tumor Conference

Course Director: William Ferrar

Course Description: Professional and post-professional course of topics in oncology and tumor biology.

MCD Biology 800/MCD Biology 890

Course Description: Student Seminars in Molecular, Cellular and Developmental Biology. Senior graduate students register for 890 and present talks. First year students attend and participate by asking questions.

Course Director: Deborah Parris

Radiology 793.1

Independent Studies/3-5 credit hours

Course Director: Robert M. Snapka

Course Description: Predoctoral research

Medical Microbiology 693.

Individual Studies.

Course Description: undergraduate research

Course Director: Robert M. Snapka

Pharmacy 993

Individual Studies in Pharmaceutical Sciences

Course Description: predoctoral research

Course Director: T. Hayton

OSBP 793

Individual Studies

Course Description: Autumn Quarter - faculty presentation of research. Winter and Spring Quarters - laboratory rotations.

Course Director: Marita King

Quarter/ Year	Course Number/ Title of Course	Enrollment	Percent of Effort	Credits	Explanation
Winter 1990	Physiol. Chem. 827 Biochemical Mechanisms of Carcinogenesis	13	7	3Cr	Team
Winter 1990	Med. Micro. 999 Dissertation Research	2	100	13Cr	Advisor
Winter 1990	Radiology 793.1 Independent Studies	1	100	3Cr	Advisor
Winter 1990	Radiology 680 Radiation Biology	18	30	2Cr	Team
Winter 1990	Vet. Pathology 640 Fundamentals of Oncology	12	10	4Cr	Team
Spring 1990	Med. Micro. 754 Medical Virology	20	3.6	4Cr	Team
Spring 1990	Med. Micro. 999 Dissertation Research	3	100	16Cr	Advisor
Spring 1990	Med. Micro. 841 Viral Oncology	10	6	3Cr	Team
Spring 1990	Radiology 850.10 Seminars in Radiobiology	5(30-40attend)	100	1Cr	Director
Summer 1990	Med. Micro 999 Dissertation Research	3	100	29Cr	Advisor
Autumn 1990	Med. Micro. 999 Dissertation Research	3	100	20Cr	Advisor
Autumn 1990	Radiology 793.10 Individual Studies	1	100	5Cr	Advisor
Winter 1991	Med. Micro. 999 Dissertation Research	3	100	24Cr	Advisor
Winter 1991	Radiology 680 Radiation Biology	15	30	2Cr	Team
Winter 1991	Vet. Pathology 640 Fundamentals of Oncology	19	10	4Cr	Team
Winter 1991	Radiology 793.10 Individual Studies	1	100	6Cr	Advisor

Quarter/ Year	Course Number/ Title of Course	Enrollment	Percent of Effort	Credits	Explanation
Spring 1991	Med. Micro. 999 Dissertation Research	3	100	23Cr	Advisor
Spring 1991	MCDBio 999 Dissertation Research	1	100	5Cr	Advisor
Spring 1991	Radiology 850.10 Seminars in Radiobiology	3	100	1Cr	Director
Spring 1991	Radiology 793.10 Individual Studies	1	100	6Cr	Advisor
Summer 1991	Med. Micro. 999 Dissertation Research	3	100	21Cr	Advisor
Summer 1991	MCDB 999 Dissertation Research	1	100	10Cr	Advisor
Summer 1991	Radiology 793.10 Individual Studies	1	100	6Cr	Advisor
Autumn 1991	Med. Micro. 625 (Med II) Pathophysiology and Manifestation of Disease	160	4	4Cr	Team
Autumn 1991	Med Micro. 999 Dissertation Research	1	100	7Cr	Advisor
Autumn 1991	MCDB 999 Dissertation Research	1	100	4Cr	Advisor
Autumn 1991	Tumor Conference Radiation & Viral Carcinogenesis	80	4.5		Team
Winter 1992	Radiology 680 Radiation Biology	15	30	2Cr	Team
Winter 1992	Med.Biochem. 827 Biochemical Mechanisms of Carcinogenesis	23	11	3Cr	Team
Winter 1992	Med Micro. 999 Dissertation Research	1	100	12Cr	Advisor
Winter 1992	MCDB 999 Dissertation Research	1	100	4Cr	Advisor

Quarter/ Year	Course Number/ Title of Course	Enrollment	Percent of Effort	Credits	Explanation
Spring 1992	Radiology 850.10 Seminars in Radiobiology	5	100	1Cr	Director
Spring 1992	Med. Micro. 999 Dissertation Research	1	100	12 Cr	Advisor
Spring 1992	Med. Micro. 841 Viral Oncology	25	6	3Cr	Team
Spring 1992	Radiology 793.10 Individual Studies	1	100	3Cr	Advisor
Spring 1992	OSBP 793 Individual Studies	1	100	2Cr	Advisor
Summer 1992	Med. Micro. 999 Dissertation Research	1	100	12Cr	Advisor
Autumn 1992	Med. Micro. 999 Dissertation Research	1	100	12Cr	Advisor
Autumn 1992	Med. Micro. 625 (Med II) Pathophysiology & Manifestation of Disease	160	4		Team
Winter 1993	Radiology 680 Radiation Biology	14	40	2Cr	Director
Winter 1993	Med. Micro. 999 Dissertation Research	1	100	12Cr	Advisor
Winter 1993	Vet Path 640 Fundamentals of Oncology	24	10	4Cr	Team
Spring 1993	Radiology 850.10 Seminars in Radiobiology	5	100	1Cr	Director
Spring 1993	Med Micro 999 Dissertation Research	1	100	12Cr	Advisor
Spring 1993	MCDB 999 Dissertation Research	1	100	2Cr	Advisor
Summer 1993	Med. Micro. 999 Dissertation Research	1	100	10Cr	Advisor
Autumn 1993	Med. Micro 625 (Med II) Pathophysiology & Manifestation of Disease	160	4		Team
Winter 1994	Radiology 680 Radiation Biology	7	40	2Cr	Director
Quarter/ Year	Course Number/ Title of Course	Enrollment	Percent of Effort	Credits	Explanation

Winter 1994	Med. Micro. 999 Dissertation Research	1	100	2Cr	Advisor
Winter 1994	MCD Biology 800 Seminar MCD Biol	18	40	1Cr	Director
Winter 1994	Vet Path 640 Fundamentals of Oncology	22	10	4Cr	Team
Winter 1994	Radiology 850.10 Molecular Carcinogenesis and Environmental Health Program Seminar	8(30-40attend)	100	1Cr	Director
Winter 1994	Med. Biochem. 827 Biochemical Mechanisms of Carcinogenesis		10.5	3Cr	Team
Winter 1994	MCD Biology 890 Seminar (Adv)	8	40	2Cr	Team Leader
Spring 1994	Radiology 850.10 Molecular Carcinogenesis and Environmental Health Program Seminar	5(30-40attend)	100	1Cr	Director
Spring 1994	Med. Micro. 999 Dissertation Research	1	100	1Cr	Advisor
Summer 1994	Med. Micro. 999 Dissertation Research	1	100	12Cr	Advisor
Autumn 1994	Radiology 850.10 Molecular Carcinogenesis and Environmental Health Program Seminar	3(30-40attend)	100	1Cr	Director
Autumn 1994	Med. Micro. 999 Dissertation Research	2	100	10Cr	Advisor
Autumn 1994	MCD Bio. 693 Individual Studies	1	100	3Cr	Advisor
Winter 1995	Radiology 680 Radiation Biology	6	40	2Cr	Director
Winter 1995	Radiology 850.10 Molecular Carcinogenesis and Environmental Health Program Seminar	2(30-40attend)	100	1Cr	Director
Winter 1995	Med. Micro. 999 Dissertation Research	1	100	10Cr	Advisor
Spring 1995	Radiology 850.10 Molecular Carcinogenesis and Environmental Health Program Seminar	1(30-40attend)	100	1Cr	Director

Quarter/ Year	Course Number/ Title of Course	Enrollment	Percent of Effort	Credits	Explanation
Spring 1995	Med. Micro. 999 Dissertation Research	1	100	12Cr	Advisor
Summer 1995	Med. Micro. 999 Dissertation Research	1	100	15Cr	Advisor
Autumn 1995	Radiology 850.10 Molecular Carcinogenesis and Environmental Health Program Seminar	3(30-40attend)	100	1Cr	Director
Winter 1996	Med. Micro. 693 Individual Studies	1	100	1Cr	Advisor
Winter 1996	OSBP 793 Individual Studies	1	100	2Cr	Advisor
Winter 1996	Radiology 680 Radiation Biology	16	40	2Cr	Director
Winter 1996	Medical Biochemistry 827 Biochemical Mechanisms of Carcinogenesis	7	10.5	3Cr	Team
Winter 1996	Med. Micro. 999 Dissertation Research	1	100	13Cr	Advisor
Winter 1996	Radiology 850.10 Molecular Carcinogenesis and Environmental Health Program Seminar	1(30-40 attend)	100	1Cr	Director
Winter 1996	Radiology 793.10 Individual Studies	1	100	4Cr	Advisor
Spring 1996	Med. Micro. 999 Dissertation Research	1	100	12Cr	Advisor
Spring 1996	Radiology 850.10 Molecular Carcinogenesis and Environmental Health Program Seminar	1(30-40 attend)	100	1Cr	Director
Spring 1996	Med. Micro. 754 Fundamentals of Molecular Virology	16	14	5Cr	Team
Spring 1996	Radiology 793.10 Individual Studies	1	100	4Cr	Advisor
Summer 1996	Med. Micro. 999 Dissertation Research	1	100	13Cr	Advisor
Summer 1996	Pharmacy 993 Individual Studies in Pharmaceutical Sciences	1	100	12Cr	Advisor
Winter 1997	Med. Microbiology 999 Dissertation Research	2	100	18Cr	Advisor

Quarter/ Year	Course Number/ Title of Course	Enrollment	Percent of Effort	Credits	Explanation
Winter 1997	Radiology 793.10 Individual Studies	1	100		Advisor
Winter 1997	Med Micro 814 Virology Journal Club	7	100		Coordinator
Winter 1997	Radiology 680 Radiation Biology	15	40	2Cr	Director
Spring 1997	Med. Microbiology 999 Dissertation Research	3	100	15Cr	Advisor
Spring 1997	Med. Micro. 754 Fundamentals of Molecular Virology	30	15	5Cr	Team
Spring 1997	Radiology 793.10 Individual Studies	1	100		Advisor
Winter 1998	Radiology 680 Radiation Biology	12	40	2Cr	Director
Winter 1999	Radiology 850.10 Molecular Carcinogenesis and Environmental Health Program Seminar	1(30-40 attend)	100	1Cr	Director
Winter 1999	Radiology 680 Radiation Biology	12	40	2Cr	Director
Winter 2000	Radiology 680 Radiation Biology	10	50	2Cr	Director
Winter 2000	Radiology 850 Grand Rounds	~80 attend		1Cr	Team
Spring 2000	Pharmaceutics 850 Seminar	30	12	1Cr	Team

2. *Involvement in Graduate/Professional Exams, Theses, and Dissertations*

a. EXAMS, THESES and DISSERTATIONS

	Number Completed	Number Current
Doctoral Students	<u>5</u>	<u>1</u>
Maqsood Wani , Ph.D. 1991, <i>Acquisition and loss of amplified genes.</i>		
Cha-Gyun Shin , Ph.D. 1991, <i>Roles of Topoisomerases in Drug-Induced Aberrant DNA Replication.</i>		
Maqsood Wani, Ph.D. 1991, <i>Acquisition and Loss of Amplified Genes.</i>		
Paskasari A. Permana , Ph.D. 1993, <i>SV40 Minichromosome: A Mammalian Replicon Model for Investigation of Antineoplastic Drugs and DNA Damaging Agents</i>		
Sung Ho Woo , Ph.D. 1998, <i>Mechanistic studies of topoisomerase II and DNA polymerase inhibitors using SV40 DNA replication.</i>		
Kuan-Chun Huang , Ph.D. 1999. <i>Characterization of SV40 host range mutants with greatly increased infectivity for human cells and mechanistic studies of XK469-a novel anti-cancer drug with topoisomerase IIb poison activity.</i>		
<u>Current:</u> Hanlin Gao		

Masters Students Plan A (thesis advisor)	_____	
Masters Students Plan B (advisor)	_____	
Doctoral Students (committee member)	<u>5</u>	<u>1</u>
Masters Students (committee member)	<u>4</u>	
Graduate School Representative	<u>4</u>	
	Number Chaired	Number Member
General Examination Committees	<u>6</u>	<u>4</u>

b. ACCOMPLISHMENTS OF GRADUATE STUDENTS

Cha-Gyun Shin (Ph.D. MM&I, 1991). Dr. Shin received the Medical Microbiology and Immunology Chairman's Research Award shortly before his graduation in 1991. He accepted a postdoctoral position in Bill Haseltine's laboratory at Harvard where he worked on the molecular biology of HIV. Dr. Shin is now on the Faculty of Biotechnology at Chung-Ang University, Korea (Ansung Campus). In 1998 he became head of his department and in 1999 he helped organize the Korean Pharmaceutical Society Meeting.

Maqsood Wani (Ph.D. MM&I, 1991). Dr. Wani received the Medical Microbiology and Immunology Chairman's Research Award in 1990. He received the Bennett Society Award for Oral Presentation of Research in 1991. He is presently a New Investigator in the NCI Program of Excellence (Dept of Microbiology/Molecular Genetics, Univ of Cincinnati, College of Medicine). He is studying the roles of specific transcription factors in development using knockout and transgenic mice in collaboration with Jerry Lingrel's laboratory.

Paskasari A. Permana. (Ph.D. MM&I, 1993). Dr. Permana did a year of postdoctoral work on gene therapy in Saswatti Chatterjee's laboratory at City of Hope National Medical Center (Pasadena, CA). She was a Research Scientist at NIH CDNS (Phoenix, AZ) until her promotion to Senior Staff Fellow in 1997.

Sung Ho Woo (Ph.D. MM&I,). Dr. Woo is currently doing postdoctoral research in St. Louis.

Kuan-Chun Huang (Ph.D. MM&I, 1999). Dr. Huang is currently doing postdoctoral research in Boston.

3. *Academic Advising*

a. **Ph.D. Primary Advisor**

Maqsood A. Wani, Medical Microbiology, Oct. 1986 - Aug. 1991.
Cha Gyun Shin, Medical Microbiology, June 1988 - Aug. 1991.
Paskasari Permana, Medical Microbiology, Oct. 1989 - 1993.
Bassem Hassan, Molecular Cellular & Dev. Biology, Jan. 1991 - 1992.
Sung Ho Woo, Medical Microbiology & Immunology, 1994 – 1998.
Alex Huang, Medical Microbiology & Immunology, 1996 - 1999
Hanlin Gao, Medical Microbiology & Immunology, 1996 - present.
Medical, Project Advisor: Paul E. Kelner, 1986-1987, Roessler Fellow, 2nd prize poster, Landacre Society

b. **Graduate Co-Advisor**

1993-1996: Sundar Venkatachalam - OSBP - Ph.D.
1985-1986: Harry L. Duran-Pharmacology-Ph.D., MARC NIH Fellow
Tapu Dutta-Choudhury-Pharmacology-Ph.D.

c. **POST PROFESSIONAL**

Shugang Ge, M.D. Post Professional Researcher March 1992 - June 1993
Patrick Moh, Ph.D., Post Professional Researcher, 1988

d. **RESEARCH ASSOCIATES AND ASSISTANTS**

Maqsood A. Wani, Research Assistant 1986-1991
Mark A. Powelson, Research Assistant 1986-1988
Susan Baird, Research Assistant 1988-1989
John M. Strayer, Research Assistant 1990
Christopher Ferrer, Research Assistant, 1993-1994
Marc Reynolds, Research Assistant, 1994 - 1996
Edith F. Yamasaki, MS, Research Associate, Laboratory Manager, 1993 – present

4. *Student Affairs Committees, Task Forces and Other Student Services*

Paul Kelner, Roessler Fellow, Project Advisor
John Strayer, SROP Minority Fellow, Project Advisor
ICSABER Graduate Student Forum, Judging Committee, May 1985
Bennett Graduate Research Society, Judging Committee, March 1987
Bennett Graduate Research Society, Judging Committee, March 1988
ICSABER Graduate Student Research Forum, Judging Committee, May 1988.
Bennett Graduate Research Society, Judging Committee, March 1990
Bennett Graduate Research Society, Judging Committee, March 1993.
ICSABER Graduate Student Research Forum, Judging Committee, 1994.
ICSABER Graduate Research Forum Judge, Spring, 1997.

5. *Chronological Listing of Publications, papers, and other creative or scholarly works.*

a. **BOOKS (OTHER THAN EDITED VOLUMES) AND MONOGRAPHS**

Snapka, R.M. (1987) Topoisomerase Inhibitors can Selectively Interfere with Different Stages of Simian Virus 40 DNA Replication. NCI Monographs, 4, pp. 55-60. Invited.

b. **BOOKS (EDITED)**

The SV40 Replicon Model for Analysis of Anticancer Drugs. 1996. Robert M. Snapka, Editor. Academic Press, San Diego. ISBN 0-12-65360-9. (Book invited by the R.G. Landes Co. Biotechnology Intelligence Unit).

c. **CHAPTERS IN EDITED BOOKS**

Snapka, R.M. Papovavirus Models for Mammalian Replicons. (1996) In: The SV40 Replicon Model for Analysis of Anticancer Drugs. (ed. R.M. Snapka) Academic Press, pp. 1-3.

Snapka, R.M. Analysis of SV40 DNA Replication Intermediates. (1996) In: The SV40 Replicon Model for Analysis of Anticancer Drugs. (ed. R.M. Snapka) Academic Press, pp. 15-34.

Snapka, R.M. Catastrophic Failure of DNA Replication Forks: Structural and Recombinational Pathways. (1996) In: The SV40 Replicon Model for Analysis of Anticancer Drugs. (ed. R.M. Snapka) Academic Press, pp. 39-61.

Snapka, R.M. and Yamasaki, E.F. Topoisomerase II and the Termination of DNA Replication. (1996) In: The SV40 Replicon Model for Analysis of Anticancer Drugs. (ed. R.M. Snapka) Acad. Press, pp. 65-83.

Snapka, R.M. DNA Damaging Agents. (1996) In: The SV40 Replicon Model for Analysis of Anticancer Drugs. (R.M. Snapka, editor) Academic Press, pp 101-109.

Snapka, R.M., Ferrer, C.A., Sun, N-J. and Cassady, J.M. (1996) Drug Discovery and Evaluation with SV40. In: The SV40 Replicon Model for Analysis of Anticancer Drugs. (R.M. Snapka, editor) Academic Press, pp. 127-148.

Snapka, R.M. and Permana, P.A.. (1996) SV40 Circular Oligomer Series: Normal and Abnormal DNA Replication Intermediates. In: The SV40 Replicon Model for Analysis of Anticancer Drugs. (ed. R.M. Snapka) Academic Press. pp. 167-187.

Finley, D., Ozkaynak, E., Jentsch, S., McGrath, J.P., Bartel, B., Pazin, M. **Snapka, R.M.** and Varshavsky, A. (1988) Molecular Genetics of the Ubiquitin System. In Ubiquitin (ed. M. Rechsteiner) Plenum Press, NY, pp. 39-75. Invited.

Varshavsky, A., Barsoum, J., Roninson, I., and **Snapka, R.M.** (1984) Acquisition and Loss of Amplified Genes: Dramatic Effects of Hormones, Tumor Promoters and Cytotoxic Drugs. In Cellular Interactions by Environmental Tumor Promoters (ed. H. Fujiki) pp. 235-254, VNU Science Press, Utrecht.

Varshavsky, A., Sundin, O., Ozkaynak, E., Pan, R., Solomon, M. and **Snapka, R.M.** (1983) Final Stages of DNA Replication: Multiply Intertwined Catenated Dimers as SV40 Segregation Intermediates. Mechanisms of DNA Replication and Recombination, pp. 463-494, Alan R. Liss, Inc., New York, NY.

d. **PEER REVIEWED JOURNAL ARTICLES**

Gao, H., Huang, K-C., Yamasaki, E.F., Chan, K.K., Chohan, L., and **Snapka, R.M.** (1999). XK469, a selective topoisomerase II β poison. *Proc. Natl. Acad. Sci. U.S.A.* **96**:12168-12173.

Huang, K-C., Yamasaki, E.F., and **Snapka, R.M.** (1999). Maintenance of episomal SV40 genomes in GM637 human fibroblasts. *Virology* **262**:457-469.

Woo, S.H., Sun, N.J., Cassady, J.M. and **Snapka, R.M.** (1999) Topoisomerase II Inhibition by Aporphine Alkaloids. *Biochem. Pharm.*, **57**:1141-1145.

Sun, N.J., Woo, S.H., Cassady, J.M. and **Snapka, R.M.** (1998) DNA polymerase and topoisomerase II inhibitors from *Psoralea corylifolia*. *J. Nat. Products*, **61**:362-366.

Snapka, R.M., Ge, S., Trask, J. and Robertson, F. (1997) Unbalanced Growth in Mouse Cells with Amplified *dhfr* Genes. *Cell Prolif.* **30**:385-399.

- Woo, S.H., Sun, N.J., Cassady, J.M. and **Snapka, R.M.** (1997) Inhibition of Topoisomerase II by Liriodenine. Biochemical Pharmacology, **54**:467-473.
- Snapka, R.M.**, Woo, S-H., Blokhin, A.V., and Witiak, D.T. (1996) Inhibition of topoisomerase II by ICRF-193, the Meso Isomer of 2,3-Bis(2,6-dioxopiperazin-4-yl)butane: Critical Dependence on 2,3-Butanediyl Linker Absolute Configuration. Biochemical Pharmacology **52**: 543-549.
- Permana, P.A., **Snapka, R.M.**, Shen, L.L., Chu, D.T.W., Clement, J.J. and Plattner, J.J. (1994) Quinobenoxazines: A Class of Novel Antitumor Quinolones and Potent Mammalian DNA Topoisomerase II Catalytic Inhibitors. Biochemistry, **33**, 11333-11339.
- Permana, P.A., Ho, D.K., Cassady, J.M. and **Snapka, R.M.** (1994) Mechanism of Action of the Antileukemic Xanthone Psorospermin: DNA Strand Breaks, Abasic Sites and Protein-DNA Crosslinks. Cancer Research, **54**, 3191-3195.
- Permana, P.A. Ferrer, C.A. and **Snapka, R.M.** (1994) Inverse Relationship Between Catenation and Superhelicity in Newly Replicated Simian Virus 40 Daughter Chromosomes. Biochem. Biophys. Res. Comm., **201**, 1510-1517.
- Permana, P.A. and **Snapka, R.M.** (1994) Aldehyde-Induced Protein-DNA Crosslinks Disrupt Specific Stages of SV40 DNA Replication. Carcinogenesis, **15**, 1031-1036.
- Snapka, R.M.** (1992) Gene Amplification as a Target for Cancer Chemotherapy. Oncology Research, **4**, 145-150. (Invited Review).
- Snapka, R.M.**, Permana, P.A., Strayer, J. and Shin, C-G. (1991) Aphidicolin-Induced Topological and Recombinational Events in Simian Virus 40. Nucleic Acids Res., **19**, 5065-5072.
- Snapka, R.M.**, Permana, P.A., Marquit, G. and Shin, C-G. (1991) Two-Dimensional Agarose Gel Analysis of Simian Virus 40 DNA Replication Intermediates. Methods: A Companion to Methods in Enzymology, **3**, 78-82.
- Wani, M.A. and **Snapka, R.M.** (1990) Hypersensitivity to Low-Level Cytotoxic Stress in Mouse Cells with High Levels of DHFR Gene Amplification. Anticancer Drugs **1**, 67-75.
- Shin, C-G. and **Snapka, R.M.** (1990) Patterns of Strongly Protein-Associated Simian Virus 40 DNA Replication Intermediates Resulting From Exposures to Specific Topoisomerase Poisons. Biochemistry **29**, 10934-10939.
- Wani, M. and **Snapka, R.M.** (1990) Drug-Induced Loss of Unstably Amplified Genes. Cancer Invest., **8**(6), 587-593.
- Shin, C-G. and **Snapka, R.M.** (1990) Exposure to Camptothecin Breaks Leading and Lagging Strand Simian Virus 40 DNA Replication Forks. Biochim. Biophys. Res. Commun., **168**, 135-140.
- Shin, C-G., Strayer, J., Wani, M. and **Snapka, R.M.** (1990) Rapid Evaluation of Topoisomerase Inhibitors: Inhibition of Topoisomerases by Caffeine. Teratogenesis Carcinogenesis Mutagenesis, **10**, 41-52.
- Wani, M.A., and **Snapka, R.M.** (1989) Methotrexate Resistance in NIH 3T3 Cells Expressing Polyoma Virus Oncogenes. Teratogenesis Carcinogenesis Mutagenesis, **9**, 369-382.
- Snapka, R.M.**, Powelson, M. and Strayer, J. (1988) Swiveling and Decatenation of Replicating SV40 Genomes In Vivo. Mol. Cell. Biol. **8**, 515-521.

Snapka, R.M. (1986) Topoisomerase Inhibitors can Selectively Interfere with Different Stages of SV40 DNA Replication. Mol. Cell. Biol. **6**, 4221-4227.

Snapka, R.M., Kwok, K., Bernard, J.M., Harling, O.K. and Varshavsky, A. (1986) Post-Separation Detection of Nucleic Acids and Proteins by Neutron Activation. Proc. Natl. Acad. Sci. USA, **83**, 8939-8942.

Snapka, R.M. and Varshavsky, A. (1983) Loss of Unstably Amplified Dihydrofolate Reductase Genes from Mouse Cells is Greatly Accelerated by Hydroxyurea. Proc. Natl. Acad. Sci. USA, **80**, 7533-7537.

Snapka, R.M. and Linn, S. (1981) Efficiency of Formation of Pyrimidine Dimers in SV40 Chromatin *in vitro*. Biochemistry, **20**, 68-72.

Snapka, R.M. and Sutherland, B.M. (1980) *E. coli* Photoreactivating Enzyme: Purification and Properties. Biochemistry, **19**, 4201-4208.

Snapka, R.M. (1979) Glass Wool as a Surface for Cell Growth *in vitro*. Tissue Culture Association Manual, **5**, No. 3, 1117-1120.

Snapka, R.M. and Fuselier, C.O. (1977) Photoreactivating Enzyme from *E. coli*. Photochemistry and Photobiology, **25**, 415-420.

Snapka, R.M., Sawyer, T.H., Barton, R.A. and Gracy, R.W. (1974) Studies on Human Triose Phosphate Isomerase. IV. Comparison of Electrophoretic Properties of the Isozymes from Various Tissues and Species. Comp. Biochem. Physiol., **49B**, 733-741.

Hendrickson, R.J., **Snapka, R.M.**, Sawyer, T.H. and Gracy, R.W. (1973) Studies on Human Triose Phosphate Isomerase. III. Characterization of Triose Phosphate Isomerase in Cri du Chat Syndrome. Amer. J. Human Genetics, **25**, 433-438.

e. **EDITOR REVIEWED JOURNAL ARTICLES**

Snapka, R.M. and Permana, P.A. (1993) SV40 DNA Replication Intermediates: Analysis of Drugs Which Target Mammalian DNA Replication. BioEssays, **15**, 121-127. (Invited review).

f. **REVIEWS AND ABSTRACTS (non-peer reviewed)**

AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics Nov. 16-19, 1999 Washington DC. XK469, a selective topoisomerase II β poison. H Gao, K-C Huang, E.F. Yamasaki, KK Chan, and **RM Snapka**.

Korean Pharmaceutical Society Meeting Oct. 1999. Seoul, South Korea. SV40 Host Range mutants Highly Infective for Human Cells. K-C Huang and **RM Snapka**.

IUPAC Symposium. International Symposium of Chemistry of Natural Products, Oct. 11-16, 1998. Beijing China. New DNA Polymerase Inhibitors from *Psoralea corylifolia*. NJ Sun, SH Woo, **RM Snapka**, JM Cassady.

R.M. Snapka, M. Reynolds, N. Sun, and J.M. Cassady. Studies on Natural Topoisomerase and DNA Polymerase Inhibitors. 37th Annual Meeting of the American Society of Pharmacognosy, University of California at Santa Cruz, July 27-31, 1996. Abstract # 228..

D.T. Witiak, A.V. Blokhin, S.S. Insaf, **R.M. Snapka** and S.H. Woo. Topoisomerase II Inhibitors: Chemistry and Biology of Bis(2,6-dioxopiperazine)s American Chemical Society Division of Medicinal Chemistry 209th ACS Meeting, Anaheim Ca. April 2-6, 1995. Abstract #34.

Yamasaki, E.F. and **Snapka, R.M.** Quantitation of Topoisomerase II Catalytic Inhibition in Intact Mammalian Cells. Abstracts, 16th International Congress of Biochemistry and Molecular Biology, New Delhi, India, September 19-22, 1994.

Woo, S.H. and **Snapka, R.M.** Recombination Events Caused by Catastrophic Failure of DNA Replication Forks. Meeting on Genetic Rearrangements and their Biological Significance. Bhabha Atomic Research Center, Bombay, India. Sept. 15-17, 1994. Abstracts, p. 46.

Permana, P. and **Snapka, R.M.** Disruption of SV40 DNA Replication by Antineoplastic Drugs and Environmental Genotoxins. BSCB Meeting on Cell Cycle Checkpoints, DNA Repair and DNA Replication. St. John's College, Cambridge, England. September 27 - October 1, 1993.

Varshavsky, A., Barsoum, J., Roninson, I.B. and **Snapka, R.M.** Acquisition and Loss of Amplified Genes: Dramatic Effects of Hormones, Tumor Promoters and Cytotoxic Drugs. Princess Takamatsu Cancer Research Fund, 14th International Symposium, Japan, 1983.

Snapka, R.M., Fuselier, C.O. and Sutherland, B.M. Photoreactivating Enzyme: Physical and Chemical Properties of the Enzyme from Escherichia coli. Biophysical Society, Twenty-first Annual Meeting, New Orleans, December 15-18, 1977.

Snapka, R.M., Sawyer, T.H., Hendrickson, R.J. and Gracy, R.W. Triose Phosphate Isomerase and Cat Cry Syndrome. Abstract, 28th Southwest Regional Meeting of the American Chemical Society, Dec. 6-8, 1972.

Snapka, R.M. and Gracy, R.W. Isolation and Properties of Human Triose Phosphate Isomerase from Human Cardiac Tissue. American Chemical Society Meeting in Miniature, April 28, 1972, Denton, Texas.

Gracy, R.W., Sawyer, T.H., **Snapka, R.M.** and Payne, D.M. Studies on Human Triose and Hexose Phosphate Isomerases. Gulf Coast Symposia on Molecular Biology, Corpus Christi, Texas, January 27-30, 1972. J. Texas Academy of Science.

Sawyer, T.H., **Snapka, R.M.**, Rozacky, E.E. and Gracy, R.W. Isolation and Properties of Human Triosephosphate Isomerase. 27th Southwest Meeting of the American Chemical Society, San Antonio, Texas, December 1-3, 1971, p.40.

Snapka, R.M. and Sutherland, B.M. (1978) Photoreactivating Enzyme from E. coli, Physical and Chemical Properties. Abstract No. 110, 7th Annual ICN-UCLA Symposia on Molecular and Cellular Biology. Keystone, Colorado. Feb. 19, 1978.

g. PAPERS IN PROCEEDINGS (non-peer reviewed)

Snapka, R.M. and Linn, S. (1980) SV40 Chromatin Structure Affects the Formation of Pyrimidine Dimers *in vitro* and Partially Protects from the Action of T4 UV Endonuclease. Fed. Proc. **39**, 415-420.

Gracy, R.W., Sawyer, T.H., **Snapka, R.M.** and Tilly, B.E. (1972) Studies on Triose Phosphate Isomerase from Human Tissues. Fed. Proc. **32**, 499.

h. POSTERS (presented at national and international meetings)

KC Huang and **RM Snapka**. SV40 Infections in Commonly Studies Human Cell Lines. Gordon Conference on Cancer, Aug. 2-7, 1998, Salve Regina University, Newport RI.

Woo, S.H., **Snapka, R.M.**, Blokhin, A.V., Sabana, S.S., and Witiak, D.T., Structure-Activity Relationships for ICRF-193 Analogs. Gordon Conference on Chemotherapy of Clinical and Experimental Cancer. 1995. Colby-Sawyer College, New London, NH.

Yamasaki, E.F. and **Snapka, R.M.** Quantitation of Topoisomerase II Catalytic Inhibition in Intact Mammalian Cells. Gordon Conference on Chemotherapy of Clinical and Experimental Cancer. 1994. Colby-Sawyer College, New Hampshire.

Snapka, R.M. Disruption of SV40 DNA Replication by Antineoplastic Agents. BSCB Meeting on Cell Cycle Checkpoints, DNA Repair and DNA Replication Strategies. St. John's College, Cambridge, England. September 27 - October 1, 1993.

Permana, P.A. and **Snapka, R.M.** Analysis of Anticancer Drugs which Target Enzymes of DNA Replication. Gordon Research Conference on Chemotherapy of Experimental and Clinical Cancer. Irsee, Germany. October 3-8, 1993.

Snapka, R.M. (1992) Gene Amplification as a Target for Anticancer Chemotherapy. Gordon Research Conference on Chemotherapy of Clinical & Experimental Cancer, Colby-Sawyer College, New London, New Hampshire. July 13-17, 1992.

Snapka, R.M. (1992). Two-Dimensional Gel Analysis of Aberrant SV40 DNA Replication. Keystone Symposia on Molecular and Cellular Biology, Molecular Mechanisms in DNA Replication & Recombination. Taos, New Mexico. January 25 - February 1, 1992.

Wani, M. and **Snapka, R.M.** (1989) Drug Induced Loss of Amplified Genes. FASEB Conference on Molecular Mechanisms of Carcinogenesis. Copper Mountain, Colorado. August 12-18, 1989.

Wani, M. and **Snapka, R.M.** (1989) Drug-Induced Loss of Amplified Genes. OLACC Conference, Michigan State University. East Lansing, Michigan. September 8-9, 1989.

Snapka, R.M., Mehta, V.M., and Muller, M.T. (1988) SV40 DNA Replication Intermediates are Selectively Associated with Both Type I and Type II Topoisomerases. Cold Spring Harbor DNA Tumor Virus Meeting. Cold Spring Harbor, NY. August 10-14, 1988.

Snapka, R.M., Mehta, V.M., and Muller, M.T. (1988) SV40 DNA Replication Intermediates are Selectively Associated with Both Type I and Type II Topoisomerases. FASEB Conference on Cellular and Molecular Genetics. Saxtons River, Vt. July 31-August 5, 1988.

Wani, M. and **Snapka, R.M.** (1987) Methotrexate Resistance and Polyoma Oncogene Expression. Sixth Cold Spring Harbor Meeting on Cancer Cells, Eukaryotic DNA Replication. Cold Spring Harbor, New York. September 2-6, 1987.

Powelson, M., Strayer, J. and **Snapka, R.M.** (1987) SV40 DNA Replication in the Presence of Topoisomerase Inhibitors. Sixth Cold Spring Harbor Meeting on Cancer Cells, Eukaryotic DNA Replication. Cold Spring Harbor, New York. September 2-6, 1987.

Wani, M. and **Snapka, R.M.** (1987) Methotrexate Resistance and Polyoma Oncogene Expression. Gordon Conference on Cancer. New London, New Hampshire. Aug. 17-21, 1987.

Snapka, R.M. (1986) Topoisomerase Inhibitors can Selectively Interfere with Different Stages of SV40 DNA Replication. First Conference on DNA Topoisomerases in Cancer Chemotherapy. NYU Medical Center, New York, New York. November 19-20, 1986.

Snapka, R.M. (1986) Topoisomerases and SV40 DNA Replication. Biomedical and Agricultural High Technology Conference. Columbus, Ohio. November 12-14, 1986.

Snapka, R.M. (1986) Topoisomerase Inhibitors can Selectively Block Different Stages of SV40 DNA Replication. FASEB Conference on Recombination and Genome Rearrangement. Saxtons River, Vermont. July 21-27, 1986.

Snapka, R.M., Barsoum, J. and Varshavsky, A. (1983) Rapid Elimination of Amplified Dihydrofolate Reductase Genes in the Presence of Sub-cytotoxic Concentrations of Hydroxyurea. Gordon Research Conference on Cancer, Colby-Sawyer College. New London, New Hampshire. August 22-26, 1983.

Snapka, R.M., Barsoum, J. and Varshavsky, A. (1983) Acquisition and Loss of Amplified Genes. FASEB Summer Research Conference on Somatic Cell Genetics, Vermont Academy. Saxtons River, Vermont. July 10-15, 1983.

Snapka, R.M. and Linn, S.M. (1980) SV40 Chromatin Structure Affects the Formation of Pyrimidine Dimers In Vitro and Partially Protects from the Action of T4 UV Endonuclease. Symposium on DNA-Multiprotein Interactions in Transcription, Replication and Repair. Gatlinburg, Tennessee. March 24-27, 1980.

6. *Other Creative Works*

Invited Lectures and Seminars Presented (non-credit)

The Solid Tumor Active Drug, XK469, is a Selective Topoisomerase II β Poison. AACR-NCI-EORC Conference on Molecular Targets and Cancer Therapeutics; Washington, DC, Nov. 16-19, 1999. **Invited Platform Speaker.**

SV40 Host Range mutants Highly Infective for Human Cells. Korean Pharmaceutical Society Meeting Oct. 1999. Seoul, South Korea, **Invited Platform Speaker.**

Analysis of topoisomerase-targeting drugs with the SV40 model system. Midwest regional meeting on Pharmacology of DNA topoisomerases and DNA repair. May 21-23, 1999. Stone laboratory Lake Erie. **Invited Platform Speaker.**

The Solid Tumor Active Drug, XK469, is a Selective Topoisomerase II β Poison. OSU CCC Scientific Retreat, Cherry Valley Lodge, Newark OH 12/16/99 **Invited Platform Speaker.**

Chemical Genetic Studies of Topoisomerase Poisons. DuPont Glenolden Research Campus 3/17/00.

Chemical Genetic Studies of Topoisomerase Poisons. National Cancer Institute, Frederick Research Campus, Frederick MD, 3/22/00

A Mechanism-Group-Specific Approach to the Discovery of Natural Products Which Disrupt DNA Replication in Mammalian Cells. R.M. Snapka, J.M. Cassidy, N.J. Sun, M. Reynolds and C. Ferrer. Midwest Regional Topoisomerase Conference, June 3-5, 1995, Stone Laboratory, Lake Erie, OH. **Invited platform speaker**

Structure-Activity Relationships for ICRF-193 Analogs. S.H. Woo, R.M. Snapka, A.V. Blokhin, S.S. Insaf, and D.T. Witiak. Midwest Regional Topoisomerase Conference, June 3-5, 1995, Stone Laboratory, Lake Erie, OH.

Alterations in Growth and Metabolism Associated with Gene Amplification - Exploitable Targets for Cancer Therapy? St. Jude Children's Research Hospital. Memphis, TN. April 28, 1995.

Recombination Events Caused by Catastrophic Failure of DNA Replication Forks. S.H. Woo and R.M. Snapka. Meeting on Genetic Rearrangements and their Biological Significance. Bhabha Atomic Research Centre, Bombay, India. Sept. 15-17, 1994. **Invited platform speaker.**

SV40 as a Model for the Mammalian Replicon in Studies of Anticancer Drugs. Department of Biochemistry, Wright State University, Dayton, OH. March 4, 1994.

Altromycins and tetracyclic antitumor quinolones. Abbott Laboratories, Waukeegan, IL April 9, 1993.

Disruption of SV40 DNA Replication by Antineoplastic Drugs and Environmental Genotoxins. British Society for Cell Biology Conference on Cell Cycle Checkpoints, DNA Repair & DNA Replication Strategies, St. John's College, Cambridge, UK, September 27 - October 1, 1993. **Invited platform speaker.**

Simian Virus 40 as a Model Mammalian Replicon. Abbott Laboratories, Abbott Park, IL, November 6, 1992.

Simian Virus 40 as a Model Mammalian Replicon. University of Maryland, College of Medicine, Baltimore, MD, November 5, 1992

Mechanism of Drug-Induced Amplified Gene Loss. Third IST Workshop on Biological and Chemical Carcinogenesis, Instituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, August 27-28, 1990. **Invited platform speaker.**

SV40 and The Swivel Problem, University of Colorado Health Sciences Center, Denver, Colorado, August 10, 1989.

SV40 and The Swivel Problem, University of Kentucky, College of Pharmacy, Lexington, KY, March 27, 1989.

Drug-Induced Loss of Amplified Genes, American Cancer Society, Research Recognition Day, The Ohio State University, Columbus, OH, June 10, 1989.

SV40 and The Swivel Problem, Public Health Research Institute, New York, NY, March 3, 1989.

Methotrexate Resistance in NIH 3T3 Cells Expressing Polyoma Virus Oncogenes, Medical Microbiology Departmental Seminar, Ohio State University, Columbus, OH, Oct. 1988.

Oncogene Expression and Cellular Interactions in Cancer Cell Resistance to Chemotherapeutic Drugs, American Cancer Society Research Recognition Day, The Ohio State University, Columbus, OH, April 1988.

Topoisomerases in SV40 DNA Replication, Department of Physiological Chemistry Seminar, The Ohio State University, Columbus, OH, November 4, 1987.

Topoisomerases in SV40 DNA Replication, Seminars in Radiobiology, The Ohio State University, Columbus, OH, April 1987.

Topoisomerases in SV40 DNA Replication, School of Life and Health Science Seminar Series, University of Delaware, Newark, Delaware. March 1987.

Acquisition and Loss of Amplified Genes, Imperial Cancer Research Foundation, Lincolns Inn Fields, London, November 9, 1984.

Acquisition and Loss of Amplified Genes: Dramatic Effects of Tumor Promoters, Hormones and Cytotoxic Drugs, CBERG seminar series, The Ohio State University, Columbus, OH, November 1984.

Acquisition and Loss of Amplified Genes, Dept. of Immunology and Infectious Disease, The Johns Hopkins University, Baltimore, MD, October 4, 1984.

Acquisition and Loss of Amplified Genes, Department of Biochemistry Seminar, University of Alabama School of Medicine and Dentistry, Birmingham, Alabama, December 15, 1983.

Drug-Induced Loss of Amplified Genes, Naval Biosciences Center, Oakland, CA, November 18, 1983.

Drug-Induced Loss of Amplified Genes, Eppley Institute, Omaha, Nebraska, November 7, 1983.

Patents

Indirect Labeling Method for Post-Separation Detection of Chemical Compounds, **R.M. Snapka**, A. Varshavsky, O. Harling, K. Kwok, V.M. Bernard. **U.S. Patent** Number 5,071,775 (Dec. 10, 1991).

7. *Research Grants*

Title	Agency*	Term	Award Amount	Total
<u>IN PROGRESS</u>				
<u>Principal Investigator</u>				
Molecular biology of Camptothecin-induced DNA Damage (Principal Investigator)	NCI 1R01 CA80961-01A2	5/08/00 through 4/30/03	Competitive Grant	\$595,688
Multi-Mechanism-Based Model for Anticancer Drugs (Principal Investigator)	NCI 1R01-CA-60914-03	9/01/95 through 8/31/00	Competitive Grant	\$603,612
<u>COMPLETED</u>				
<u>Principal Investigator</u>				
Mechanism Group Strategy for Discovery and Analysis of Anticancer Drugs	ACS DHP-137	01/01/95 through 12/31/95	Competitive Grant	200,000
Multi-Mechanism Based Model for Anticancer Drugs	OSUCCC (NCI)	7/1/93 through 6/30/95	Competitive Grant	87,600
Pre-DNA Cleavage Inhibition of Topoisomerase II In Vivo	ACS-Ohio	9/1/94 through 8/31/95	Competitive Grant	13,000
Multidrug Resistance Gene Amplification in Methotrexate Resistance	ACS CH-361C	7/1/90 6/30/93	Competitive Grant	193,000
Aberrant Papovavirus Replication After Genotoxic Damage	NCI 5 R29- CA 45208	7/1/87 5/31/93	Competitive Grant	423,494
Patterns of Macromolecular Synthesis During the Acquisition and Loss of Amplified Genes	ACS CH-361B	7/1/88 6/30/90	Competitive Renewal	143,000
Patterns of Macromolecular Synthesis During the Acquisition and Loss of Amplified Genes	ACS CH-361	7/1/86 6/30/88	Competitive Grant	133,986
Curing Mammalian Cells of Amplified DNA Sequences	ACS-Ohio 20176-55-00	7/1/85 6/30/86	Competitive Grant	7,270
Patterns of Macromolecular Synthesis in Stressed Populations of Mammalian Cells	OSU Seed Grant 221878	5/1/86 4/30/87	Competitive Grant	10,000

Title	Agency*	Term	Award	Total Amount
-------	---------	------	-------	--------------

COMPLETED**Principal Investigator (cont'd)**

Aberrant DNA Replication in Papovaviruses	ACS-OSUCCC IN-16X	7/1/85 6/30/86	Competitive Grant	4,000
Gene Amplification	OSU Small Grant 1095	9/1/85 3/31/86	Non-competitive Grant	1,000
Topoisomerases as Targets for Chemotherapy	OSU-CCC 244605	9/1/86 6/30/87	Non-competitive Grant	18,000
DNA Damage Following Exposure to Genotoxin (P.I.: Altaf A. Wani)	NIEHS 5 R01- ES02388-11	12/01/88 11/30/94	Competitive Grant	786,442
DNA Damage in Oncogene Activation (P.I.: Altaf A. Wani)	NCI R01-CA 39397	9/30/87 8/31/91	Competitive Grant	291,341

PENDING

Molecular Targets Related To DNA and Chromatin (PI: M.R. Grever)	NCI RFA	12/01/00 11/30/05	Competitive Grant	6,161,953
--	------------	----------------------	----------------------	-----------

*ACS - American Cancer Society
 NCI - National Cancer Institute
 OSU - Ohio State University Graduate School
 OSUCCC - Ohio State University Comprehensive Cancer Center
 NIEHS - National Institute of Environmental Health Science

Fellowships

PHS Nat. Inst. of Gen. Med. Sci. (GM-07311-02) PI: B.M. Sutherland
Predoctoral, Department of Molecular Biology and Biochemistry, U.C. Irvine. Period 7-1-76 to 6-30-77.
National Institutes of Health (5F32-GM-06587-03) PI: **R.M. Snapka**
Postdoctoral, Department of Biochemistry, U.C. Berkeley. Period: 5-22-78 to 5-22-81.
Flow General Royalty Fund (Fellow) PI: A. Varshavsky
Postdoctoral, Department of Biology, Massachusetts Institute of Technology. Period 2-1-82 to 1-31-84.

Other

Travel Grant Award 16th ICBMB meeting New Delhi, India Sept 1994.

8. *Editorship of journals or other learned publications*

Reviewer: Photochem. Photobiol., 1984.
Reviewer: Neurochemical Pathology, 1985.
Reviewer: Biochemical Pharmacology, 1992.
Reviewer: Cancer Research, 1993.
Reviewer: Journal of Molecular Biology, Dec. 1994.
Reviewer: Journal of Molecular Biology, Aug. 1994.
Reviewer: Chromosoma, 1995.
Editor: The SV40 Replicon Model for Analysis of Anticancer Drugs.
Academic Press and RG Landes Co. 1996. San Diego.
Reviewer: Biochemical Pharmacology, Nov. 1996.
Reviewer: Biochemical Pharmacology, Nov. 1997.
Reviewer: Biochemistry, April, 1999.
Book Reviewer: Quarterly Reviews of Biology. 1999.

9. *Offices held and other service to professional societies*

Member, Biophysical Society (elected)
Member, American Association for the Advancement of Science (open)
Member, Alpha Chi Sigma Professional Chemistry Society (elected)
Member, American Society for Microbiology (open)
Member, American Society of Pharmacognosy (open)
Member, The Society of Biomolecular Screening (open)

10. *Consultation*

Abbott Laboratories, Consultant on developmental drug mechanisms. 1992-1993.
Reviewer: Ohio Cancer Research Association, 1991.SV40 NA Replication,
Ad Hoc Reviewer, NCI: June 1995, Bio-Organic and Natural Products Chemistry study section.
Ad Hoc Reviewer, NCI: Oct. 23-24, 1997, Experimental Therapeutics Study Section.
NIH/NCI Program Project Site Visit Team Member: DNA Topoisomerase I Targeted Therapy of
Colon Cancer. New York University, September 1995.
Ad Hoc Reviewer, NCI RAID Study Section, 3/31-4/1, 1999.
Ad Hoc Reviewer, NCI Cytology study section, Jan. 1999.
Reviewer, NIH PNP Special Study Section, Aug. 19, 1999.
External Evaluator for Promotion: Dept. of Pharmacology and Experimental Therapeutics, Univ. of
Maryland, (Edison X. Albuquerque, Chairman) 1993.
External Evaluator for Promotion: Dept. of Pharmaceutical Sciences, School of Pharmacy,
University of Maryland (E.Morton, Chairman). Dec. 1995.
External Evaluator for Promotion: Department of Pharmacology and Toxicology, Medical College of
Virginia, Richmond Va. (Steven Grant, MD, Chairman)
External Reviewer, Henry Ford Health Center, 10/04/99

11. *Other Professional Service*

Participant, NY Academy of Sciences Meeting on Camptothecins. Ritz-Carlton, Pentagon City VA, 3/17/00-3-19/00.

Participant, Symposium, Eukaryotic DNA Replication: Proteins at the Fork, Gulf Shores, Alabama, April 26-29, 1990.

Invited Platform Speaker, Third IST Workshop on Biological and Chemical Carcinogenesis, Instituto Nazionale per la Ricerca sul Cancro, Genoa, Italy. August 27-28, 1990.

Invited Platform Speaker, British Society for Cell Biology, Conference on Cell Cycle Checkpoints, DNA Repair and DNA Replication Strategies, St. John's College, Cambridge, UK September 27-Oct 1, 1993.

Invited Platform Speaker, Meeting on Genetic Rearrangements and their Biological Significance. Bhabha Atomic Research Centre, Bombay, India. September 15-17, 1994.

Co-Organizer & Invited Platform Speaker: First Midwest Regional Topoisomerase Conference, Stone Lab, Put-in-Bay, Ohio, June 3-5, 1995.

Invited Platform Speaker: Midwest regional meeting on Pharmacology of DNA Topoisomerases and DNA Repair, Stone Laboratory, Lake Erie OH, May 21-23, 1999.

Reviewer, Children's Hospital Seed Grants, 1990

Reviewer, Starter Grant Children's Hospital Research Foundation, July 1990.

Reviewer, University Seed Grant Proposals, Nov. 19, 1991.

Reviewer, College of Medicine Research Committee, November 1993.

Reviewer, OSU Oncology Training Grants, December 1994, (10), Jan 22, 1996, (5) March, 1995.

Reviewer, Carcinogenesis Training Grant Applications, January 1995, 1996.

Member, Ex. Committee for Carcinogenesis, Molecular & Cellular Biology Training Grant, Jan. 11, 1995.

Reviewer, OSU Comprehensive Cancer Center Pilot Grants (11) 1989, (9) 1990.

Reviewer, ACS Seed Grants (2), March 1995, (2), Nov. 1995

Reviewer, P20 Program Development Grant in Breast Cancer - Pilot project proposals, June 1995.

Designed and Installed Web Site. Dept. of Medical Microbiology and Immunology, 1996

OSU representative at the NIEHS public discussion of the Superfund Hazardous Substance Basic Biomedical Research and Training Grant Program. Research Triangle Park, December 15, 1986.

Representative, Department of Radiology. OSU College of Medicine Faculty Retreat. Salt Fork, Ohio, October 5-7, 1989. Member: working group on class size.

Reviewer, OSU Comprehensive Cancer Center Pilot Grants (3) 1987, (11) 1989.

Reviewer, University Seed Grant Proposals, 1986.

12. *Administrative Service*a. **Departmental Committees**

Department of Medical Microbiology & Immunology Graduate Committee, 1990-1996.

Department of Medical Microbiology & Immunology Faculty Search Committee, 1991.

Department of Medical Microbiology & Immunology Medical Education Committee, 1988.

Department of Radiology Ad hoc Committee for Revision of P&T Procedures 1997

Department of Radiology Promotion & Tenure Committee 1998-2000.

b. **College or University committees**

OSBP Graduate Admissions, 1990, 1991.

College of Medicine Graduate Education Committee 1988-1989, 1991-present

Bennett Fellowship Committee, 1994, 1996, 1999.

Biotechnology Advisory Committee, 1989.

College of Medicine Graduate Education Committee 1988, 1989

Member working group on class size, OSU College of Medicine Faculty Retreat at Salt Fork, Ohio. Oct. 5-7, 1989.

c. **Participation in affirmative action programs or special assignments**

Research Advisor for John Strayer, SROP Minority Fellow, summer quarter 1988.